Investing in dividend stocks is generally reserved for those who prefer steady returns and low volatility over the thrill of rapid potential gains. Investors saw tech stocks explode in 2023 as artificial intelligence emerged. In 2024, investors expect further growth but are also hesitant.Economists believe that a soft landing is the most likely scenario. Let’s all hope that that’s the case. However, it also makes sense to bolster your portfolio simultaneously with the safety of dividend stocks.As with all o ...

Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments.Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures ...

cagkansayin Introduction It's time to talk about one of my favorite dividend investments. A company that has both an elevated yield of 3.7% and consistent dividend growth, making it a great investment for a very wide range of investors. That company is AbbVie (NYSE:ABBV), a stock I covered on November 29 in an article titled 4.5%-Yielding AbbVie Is One Of My Favorite Value Plays For 2024." Here's a part of the takeaway I used back then: Despite the prevailing underperformance of value stocks since 20 ...

Income-seeking investors usually don't think of the innovation-dependent pharmaceutical industry as a place to look for businesses with reliable cash flows.Dividend seekers have a good reason to be cautious regarding drugmaker stocks. Profit driven by patent-protected market exclusivity can disappear in the blink of an eye after those patents expire. These two giants of the pharmaceutical industry are made of enough moving pieces that when one blockbuster falls off a patent cliff, there's another on deck to ...

Key TakeawaysAbbVie Inc. reported profit and sales that beat estimates, and raised its guidance on two of its key drugs.The pharmaceutical company's revenue was fueled by immunology treatments Skyrizi and Rinvoq.AbbVie said it now anticipates Skyrizi and Rinvoq will bring in sales of $27 billion by 2027.AbbVie Inc. (ABBV) shares traded near their all-time high Friday as the pharmaceutical company posted better-than-expected results and raised its sales forecast for two of its key medicines.AbbVie reported f ...

AbbVie Inc. (ABBV) reported adjusted earnings of $2.79 per share for fourth-quarter 2023, beating the Zacks Consensus Estimate of $2.76. The reported earnings also exceeded the guidance of $2.72-$2.76. However, earnings declined 22.5% year over year.ABBV’s revenues of $14.30 billion beat the Zacks Consensus Estimate of $14.05 billion. Sales declined 5.4% year over year, both on a reported basis and an operational basis. The downside was caused by lower sales of Humira and Imbruvica, which was partially offs ...

Financial Data and Key Metrics Changes - AbbVie reported total net revenues of $54.3 billion for the year, exceeding initial guidance by approximately $2.3 billion [9] - Adjusted earnings per share for the full year were $11.11, which is $0.63 above the initial guidance midpoint [9] - The adjusted operating margin ratio was 43.8% of sales, with an adjusted gross margin of 83.9% [39] Business Line Data and Key Metrics Changes - The growth platform excluding Humira delivered full-year sales growth of over 8%, with revenue growth accelerating to more than 15% in Q4 [6] - Immunology revenues exceeded expectations, with Skyrizi sales at approximately $2.4 billion (51.6% operational growth) and Rinvoq at over $1.2 billion (62.8% operational growth) [15] - Oncology revenues totaled $1.5 billion, with Imbruvica down 19% to $903 million and Venclexta up 13.7% to $589 million [19] - Aesthetics sales were approximately $1.4 billion, with U.S. Botox Cosmetic sales increasing by 7.3% [24] Market Data and Key Metrics Changes - Global sales for Skyrizi are expected to exceed $17 billion by 2027, while Rinvoq is anticipated to achieve over $10 billion in the same timeframe [13] - The U.S. market for Humira saw a 40.8% decline due to biosimilar competition, with global sales at $3.3 billion [18] - Neuroscience revenues were over $7.7 billion for the year, reflecting nearly $1.2 billion in growth [21] Company Strategy and Development Direction - AbbVie is focused on driving strong performance from its ex-Humira growth platform, with key brands expected to contribute double-digit sales growth in 2024 [10] - The company plans to prioritize investments in its pipeline, with several important R&D programs anticipated for updates this year [11] - AbbVie aims to close and integrate the acquisitions of ImmunoGen and Cerevel, which are expected to enhance revenue growth into the next decade [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in returning to operational sales growth in 2024, one year after the Humira loss of exclusivity [8] - The long-term sales outlook includes a return to robust revenue growth in 2025, with a high single-digit CAGR through the end of the decade [12] - Management highlighted the significant growth potential in the immunology market, particularly for Rinvoq and Skyrizi [53] Other Important Information - AbbVie increased its quarterly dividend, which has grown by more than 285% since inception [7] - The company expects to generate free cash flow of approximately $18 billion in 2024, supporting dividend growth and debt repayment [45] Q&A Session Summary Question: Long-term immunology outlook and growth drivers - Management indicated that there is significant headroom for growth in immunology, with both Rinvoq and Skyrizi expected to contribute to revenue growth beyond 2027, with Rinvoq likely having a higher growth rate due to new indications [50][55] Question: Succession planning update - Management stated that there is no new update on succession planning but emphasized that the transition will occur when the business is performing at a high level post-Humira LOE [58][60] Question: Commercial opportunity for lutikizumab in HS - Management highlighted that HS is a significant commercial opportunity, with expectations for continued market expansion and the potential for lutikizumab to succeed in IBD due to its mechanism of action [63][64] Question: Impact of RNA IRA-mediated price cuts - Management believes that the impact of IRA negotiations will be largely contained to the Medicare side and will not significantly affect the commercial market [67] Question: Plans for ImmunoGen acquisition and earlier lines of therapy - Management discussed strategies to move Elahere into earlier lines of ovarian cancer therapy, focusing on sensitive populations and combination therapies [71]

The big jobs numbers out this week came from this morning’s U.S. Bureau of Labor Statistics' (BLS) Employment Situation report, which surprised to the upside in a major way: 353K new jobs created for January, nearly double the 180K or so analysts were looking for. A big upward revision for December accompanies this headline, from 216K originally reported to 333K today. These are far and away the strongest months for jobs gains in the past 12 months. The Unemployment Rate stayed at 3.7%, where it’s been for ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

The big jobs numbers out this week came from this morning’s U.S. Bureau of Labor Statistics' (BLS) Employment Situation report, which surprised to the upside in a major way: 353K new jobs created for January, nearly double the 180K or so analysts were looking for. A big upward revision for December accompanies this headline, from 216K originally reported to 333K today. These are far and away the strongest months for jobs gains in the past 12 months. The Unemployment Rate stayed at 3.7%, where it’s been for ...